Alternative splicing and mutation status of CHEK2 in stage III breast cancer.
about
The CHEK2 gene and inherited breast cancer susceptibilityCheckpoint Kinase 2 Negatively Regulates Androgen Sensitivity and Prostate Cancer Cell Growth.Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibitionCHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancerDNA damage during reoxygenation elicits a Chk2-dependent checkpoint responseAlteration of introns in a hyaluronan synthase 1 (HAS1) minigene convert Pre-mRNA [corrected] splicing to the aberrant pattern in multiple myeloma (MM): MM patients harbor similar changes.Fusion of the tumor-suppressor gene CHEK2 and the gene for the regulatory subunit B of protein phosphatase 2 PPP2R2A in childhood teratomaBreast tumors from CHEK2 1100delC-mutation carriers: genomic landscape and clinical implications.Alternative splicing of CHEK2 and codeletion with NF2 promote chromosomal instability in meningioma.Genomic profiling of CHEK2*1100delC-mutated breast carcinomas.CHEK2 contribution to hereditary breast cancer in non-BRCA familiesLow expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.Heterozygous screen in Saccharomyces cerevisiae identifies dosage-sensitive genes that affect chromosome stability.Multiple endocrine neoplasia type 1 (MEN1) as a cancer predisposition syndrome: clues into the mechanisms of MEN1-related carcinogenesis.Strength and weakness of phase I to IV trials, with an emphasis on translational aspects.Aberrant splice variants of HAS1 (Hyaluronan Synthase 1) multimerize with and modulate normally spliced HAS1 protein: a potential mechanism promoting human cancerPrevalence of the CHEK2 R95* germline mutationMapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers.RNA splicing: a new player in the DNA damage responseMicroRNA-191 promotes osteosarcoma cells proliferation by targeting checkpoint kinase 2.CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute.Centrosomal Chk2 in DNA damage responses and cell cycle progression.Evidence of the modulation of mRNA splicing fidelity in humans by oxidative stress and p53.Zinc finger transcription factors designed for bispecific coregulation of ErbB2 and ErbB3 receptors: insights into ErbB receptor biology.Genomic analysis of cancer tissue reveals that somatic mutations commonly occur in a specific motif.High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function.An extensive program of periodic alternative splicing linked to cell cycle progression.A novel peroxisome proliferator-activated receptor gamma isoform with dominant negative activity generated by alternative splicing.Adjuvant treatment: the contribution of expression microarrays.Chk2 oligomerization studied by phosphopeptide ligation: implications for regulation and phosphodependent interactions.Restoration of fragile histidine triad expression restores Chk2 activity in response to ionizing radiation in oral squamous cell carcinoma cells.Malfunctioning DNA damage response (DDR) leads to the degeneration of nigro-striatal pathway in mouse brain.TP53 and additional pathways in therapy resistance.Genetic and epigenetic analyses guided by high resolution whole-genome SNP array reveals a possible role of in Wilms tumour susceptibility
P2860
Q28265315-D7B83592-D2EA-43C4-ACDB-4A14EA3E2970Q28395484-86BC6893-10BC-484F-85D0-EE76B26F53F1Q28396027-480F7658-CD49-40D0-A6AB-2E508E3A22B3Q28473504-EC882E1A-DBF7-48E3-A5FA-676D91AC3E7BQ34519722-2E7DCDDB-74CF-49E2-BD2F-7BBBE903D682Q34542508-4FE3FA53-834F-4E36-B152-A8CF931FAC04Q35070054-358EB83A-3989-47C4-843B-9D42E6166CB5Q35683548-2A8A8A2E-2B04-421A-A8BF-BD51C0AC05E3Q35763880-24272E8A-0E1E-431F-B03A-A183BA31BFE3Q35836700-90BAEC1D-502A-4C9A-B722-8BAA7F7D0086Q35889614-28824931-BB0D-4F41-80A3-BC6AEBF33D48Q36245541-D405A238-02F3-44AB-9C1C-8A46F41B1F12Q36515688-5FCB0ED3-5536-4A8C-8BCB-8ACCADFD3C21Q36973287-3F6A7A87-EC37-4061-A139-F1171D4B3C61Q37039810-F63BBB19-704B-40F9-91C3-E1C23AFAA202Q37253985-CAC09036-706B-4F52-B130-984A24DFF0BDQ37291784-D62CF279-BE35-4A06-92B8-FBE4CC7D30F5Q38087850-8E4A6796-0300-43F8-B255-B8E6112C0328Q38155497-6FF24B77-BE00-46FA-A267-B3AA09F153D3Q38899676-5B8DDC46-9C04-49A1-87D1-B185D4001076Q39505275-0AC29463-90B9-4057-AB39-F01803DE2E4BQ39676551-411C5831-C7D0-473F-BB57-F3DB3178A5FBQ40039529-B9EC894E-9355-44CB-A2FD-D9B2AE249236Q40366552-E6F18A8B-F650-4CA5-AB8D-BBC28D4088EEQ41812715-0F92EA75-6D79-4577-9DBB-B0D60B087E65Q41899812-44CF6D07-F0D9-4FE5-B872-6C642E56E4F2Q42754639-0672DBF8-419A-4576-A3D6-EF3F157F0BCCQ42815399-9261BA53-138F-45BA-8545-E43563E80909Q45788484-B81070C9-D2D9-4A07-A829-EF3CC8812915Q46299925-EC9E1AB3-6793-44A7-AF2D-BD765957F0ADQ46826896-34AB2F00-685D-4D47-ABD7-836EB708068CQ48895419-D3E1EB90-77F8-432F-BDA3-5506123CC574Q50104546-9AD4D5EB-FECD-40A4-8472-1353E97911E7Q57821557-56C148DA-E977-4131-805A-12B10F58BEAC
P2860
Alternative splicing and mutation status of CHEK2 in stage III breast cancer.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Alternative splicing and mutation status of CHEK2 in stage III breast cancer.
@en
Alternative splicing and mutation status of CHEK2 in stage III breast cancer.
@nl
type
label
Alternative splicing and mutation status of CHEK2 in stage III breast cancer.
@en
Alternative splicing and mutation status of CHEK2 in stage III breast cancer.
@nl
prefLabel
Alternative splicing and mutation status of CHEK2 in stage III breast cancer.
@en
Alternative splicing and mutation status of CHEK2 in stage III breast cancer.
@nl
P2093
P2860
P50
P356
P1433
P1476
Alternative splicing and mutation status of CHEK2 in stage III breast cancer.
@en
P2093
Jacob Falck
Johan Richard Lillehaug
Vidar Staalesen
P2860
P2888
P304
P356
10.1038/SJ.ONC.1207928
P407
P577
2004-11-01T00:00:00Z